Primary adenocarcinoma of the renal pelvis, ureter and the urinary bladder: A case report and review of the literature (2024)

  • Journal List
  • Oncol Lett
  • v.11(3); 2016 Mar
  • PMC4774608

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice

Primary adenocarcinoma of the renal pelvis, ureter and the urinary bladder: A case report and review of the literature (1)

Link to Publisher's site

Oncol Lett. 2016 Mar; 11(3): 1811–1814.

Published online 2016 Jan 26. doi:10.3892/ol.2016.4151

PMCID: PMC4774608

PMID: 26998081

XING XIONG,* LINGHUA JIA,* and JINGEN WANG

Abstract

Primary adenocarcinoma is a rare type of urological neoplasm. The present study reports the case of a 55-year-old man with multifocal adenocarcinoma of the renal pelvis, ureter and urinary bladder that occurred in association with a large cystic calculus and perinephric abscess. The patient had suffered from gross hematuria for 2 years and right flank pain for 2 months. Following a series of investigations, a large cystic calculus with multiple tumors in the renal pelvis and ureter was identified. Multifocal tumors and a large calculus were located in the bladder using a cystoscope. The pathological report of 3 individual biopsies revealed a moderately differentiated tubular adenocarcinoma. Right nephrectomy, ureterectomy, radical cystectomy and left ureterocutaneostomy were performed. The pathological investigation revealed a moderately differentiated adenocarcinoma of the renal pelvis, ureter and urinary bladder. No additional treatment was administered and the patient remains alive at follow-up without disease recurrence or metastasis. Although uncommon, the development of a tumor is possible in patients that possess long-standing urolithiasis, particularly when accompanied by hydronephrosis or infection.

Keywords: adenocarcinoma, cystic calculus, renal pelvic tumor, ureter tumor, bladder tumor

Introduction

The majority of malignant renal pelvic and ureteral tumors are of epithelial origin (1). Among these, ~90% are transitional cell carcinoma (1). Transitional cell carcinoma cells grow in aggregates, whilst adenocarcinoma cells grow in tubules, with abundant cytoplasm and enlarged, hyperchromatic nuclei. However, pure adenocarcinomas of the urothelium are rare, accounting for <1% of all urothelial tumors; and for adenocarcinomas to be located in the pelvis is uncommon (2). Adenocarcinoma of the urinary bladder is also a rare malignancy that accounts for <2% of the primary bladder cancers (3,4). Common treatment may include nephrectomy, ureterectomy and partial cystectomy (5). The present study reports a case of multifocal primary adenocarcinoma of the renal pelvis, ureter and urinary bladder that occurred in association with a large cystic calculus and perinephric abscess.

Case report

A 55-year-old male nonsmoker presented with gross hematuria that had lasted for two years, right flank pain that had lasted for two months and no fever. At the time of admission, the patient's body temperature and blood pressure were 37.1°C and 107/69 mmHg, respectively. A general physical examination revealed pallor. The abdominal examination revealed a 20×15 cm smooth, firm, non-tender and ballotable mass in the right lumbar area that extended to the right hypochondrium. Routine hematological investigations revealed a white blood cell count of 7.9×109 cells/l (normal range, 3.5×109−9.5×109 cells/l), a hemoglobin level of 89 g/l (normal range, 130–175 g/l) and a platelet count of 493×109 platelets/l (normal range, 100×109 −300×109 platelets/l). The urine examination revealed packed pus cells and red blood cells, and the culture was sterile. The plain abdominal radiograph revealed large cystic calculi. The computed tomography (CT) scan revealed a multifocal tumor in the right pelvis and ureter and a normally-functioning left kidney (Fig. 1). Technetium-99m diethylene-triamine-pentaacetic acid renal scintigraphy revealed a non-functioning right kidney. The cystoscope revealed large calculi in the bladder and multifocal tumors along the wall of the urinary bladder. The pathological report of 3 tissue samples revealed a moderately differentiated tubular adenocarcinoma.

Open in a separate window

Figure 1.

Computed tomography revealed a multifocal tumor in the right pelvis and ureter and a normally functioning left kidney.

The diagnosis was multifocal carcinoma of the renal pelvis, ureter and urinary bladder, which occurred in association with a large cystic calculus and perinephric abscess. Right nephrectomy, ureterectomy, radical cystectomy and left ureterocutaneostomy were performed. Intraoperatively, the right kidney was markedly enlarged, possessed a perinephric adhesion and abscess and contained ~1,500 ml of urine in the renal pelvis. The right ureter was dilated, markedly enlarged and contained a perinephric adhesion. A gross pathological examination revealed that the kidney and attached ureter measured 13×8×6 cm and 17×3 cm, respectively. The bladder measured 8×7×3 cm and the attached prostate was 3×3×1 cm. The cut section revealed a dilated calyx, which exhibited the loss of the corticomedullary junction, and multifocal tumors in the renal pelvis, ureter and urinary bladder that were associated with a large cystic calculus (Fig. 2). Microscopic examinations revealed the characteristics of adenocarcinoma. It was observed that the cells were growing in tubules, and exhibited abundant cytoplasm and enlarged, hyperchromatic nuclei (Fig. 3). Lymphovascular and perinephric fat invasions were not observed. No additional treatment was administered and the patient remains alive at follow-up with no tumor recurrence or metastasis.

Open in a separate window

Figure 2.

(a) The right kidney. (b) The right ureter. (c) Multifocal tumors in the ureter. (d) The large cystic calculus.

Open in a separate window

Figure 3.

Microscopic examination revealed the characteristics of adenocarcinoma. The cells were growing in tubules, exhibiting abundant cytoplasm and enlarged, hyperchromatic nuclei. Staining, hematoxylin and eosin; magnification, ×100.

Discussion

The majority of tumors of the renal pelvis and ureter have a distinct pathology (1). The most frequently observed tumor is urothelial carcinoma, which accounts for 90% of all renal pelvis and ureter tumors (1). The other tumors observed tend to be squamous cell carcinoma, adenocarcinoma or leiomyosarcoma (1). Among the special types of tumors, primary adenocarcinomas are relatively uncommon, and account for 1% of all renal, pelvis and ureter tumors (2). Only a small number of individual cases are reported in the literature. Renal pelvic and ureter adenocarcinomas are often associated with chronic inflammation and subsequent chronic infection, hydronephrosis and urinary calculi (6,7). In 1946, Ackerman reported the first case of mucinous adenocarcinoma of the pelvis (8). At present, ~100 cases have been reported in the English medical literature (PubMed, Elsevier, Medline, Springer and EBSCO). The highest numbers of reported cases are from Japan (12 cases) and India (10 cases), while other areas of the world have reported occasional cases (9).

The pathogenesis of the present renal pelvis and ureter tumors is not clear. The suggested pathogenesis considers the frequent association with chronic irritation, infection, inflammation, hydronephrosis and urinary calculi. Glandular metaplasia of the urothelium may develop as a response to injury, and can often progress to dysplasia and adenocarcinoma (10). The majority of cases are reported in patients older than 60 years, and there is no evidence to suggest that the occurrence of the tumor is associated with gender (5,11). Hematuria is the most common symptom at presentation, while loin pain and a palpable abdominal mass signifies a late stage in the disease; however, patients may be asymptomatic (12). Over two thirds of cases are associated with urolithiasis and hydronephrosis (12).

In addition to urothelial adenocarcinoma, adenocarcinoma of the urinary bladder is a rare malignancy that accounts for <2% of primary bladder cancers (13,14). Adenocarcinoma may be classified into three groups, consisting of the primary vesicle, urachal and metastatic adenocarcinomas (12). Metastatic adenocarcinoma is one of the most common forms of adenocarcinoma (15). The diagnosis, treatment and prognosis of metastatic adenocarcinoma are closely associated with the primary site, which may include the rectum, stomach, endometrium, breast, prostate or ovary (6). Adenocarcinoma of the bladder is considered to be associated with a poor prognosis in the majority of studies (13). However, previous observations indicate that bladder adenocarcinoma may have the same natural history as urothelial adenocarcinoma. An analysis of survival rate from the Netherlands Cancer Registry indicated that the survival of patients with muscle-invasive bladder adenocarcinoma is similar to the survival of patients with muscle-invasive urothelial carcinoma (16). Ghoneim et al (17) also identified that there are no statistical differences between bladder and urothelial carcinomas in terms of mortality.

Adenocarcinomas of the urinary bladder may be subclassified into urachal (U) and non-urachal (NU) adenocarcinomas (14). Zhang et al (14) reviewed the data of 21 cases with primary adenocarcinoma of the bladder over a 10-year period, in order to investigate the variation between urachal and non-urachal adenocarcinomas in terms of patient survival. Numerous studies agree that urachal and non-urachal tumors probably exist together in the majority of cases (14,18). Although the two tumors possess the same pathogenesis, there appears to be clinical differences between the two types. At present, it remains unclear whether the survival of patients with urachal adenocarcinoma varies from that of patients with non-urachal adenocarcinomas. Wright et al (19) identified that urachal cancer possessed a significantly better prognosis than non-urachal cancer, while Mostofi et al (20) hypothesized that urachal adenocarcinomas were associated with a significantly worse prognosis. In addition, Dandekar et al (21) considered there to be no significant differences between the two carcinomas. Zhang et al (14) identified that urachal adenocarcinoma was associated with a more favorable outcome. However, the variation between the two types was not statistically significant using the Kaplan-Meier estimates (P=0.0763).

Primary adenocarcinoma of the urological region requires differentiation from more common metastatic adenocarcinomas, including direct, lymphatic and hematogenous spread (22,23). The principal primary organs to be considered include the prostate, colon, female genital tract, appendix, stomach and breast (22,23). The presence of a flat carcinoma in situ provides evidence to support the theory that a primary vesical adenocarcinoma may be considered a separate entity (24,25). Flat carcinomas in situ are challenging to document, particularly in transurethral resection specimens due to extensive thermal artifacts that may be caused by complete sampling, and the presence of mucosal ulcerations (24,25). Also, secondary adenocarcinoma tends to colonize the native epithelium, which may mimic a carcinoma in situ component (24,25). The most frequent and challenging differential diagnosis remains to be metastatic or directly spreading colonic adenocarcinoma. The latter is virtually indistinguishable based on histomorphology and immunohistochemistry (24,25). Therefore, differential diagnosis is even more challenging on small biopsies that possess poorly differentiated tumors.

Lauritzen et al (26) and Sidharth et al (27) reported cases of patients that underwent a radical nephrectomy and total ureterectomy, including an ipsilateral bladder cuff excision, to treat a primary carcinoma of the upper urinary tract. The patient in the present study was possessed multifocal adenocarcinoma of the renal pelvis, ureter and the urinary bladder that occurred in association with a large cystic calculi and perinephric abscess. To the best of our knowledge, the present study is the first to report a case of this type. Right nephrectomy, ureterectomy, radical cystectomy and left ureterocutaneostomy were performed. The patient has now lived without a tumor for 6 months.

References

1. Spires SE, Banks ER, Cibull ML, Munch L, Delworth M, Alexander NJ. Adenocarcinoma of renal pelvis. Arch Pathol Lab Med. 1993;117:1156–1160. [PubMed] [Google Scholar]

2. Sagnotta A, Dente M, Socciarelli F, Cacchi C, Stoppacciaro A, Balducci G. Primary adenocarcinoma of the renal pelvis: Histologic features of a stepwise process from intestinal hyperplasia to dysplasia in a patient with chronic renal abscess. Int J Surg Pathol. 2014;22:182–185. doi:10.1177/1066896913502225. [PubMed] [CrossRef] [Google Scholar]

3. Roy S, Smith MA, Cieply KM, Acquafondata MB, Parwani AV. Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: A persisting diagnostic challenge. Diagn Pathol. 2012;7:151. doi:10.1186/1746-1596-7-151. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Nielsen K, Nielsen KK. Adenocarcinoma in exstrophy of the bladder - the last case in Scandinavia? A case report and review of literature. J Urol. 1983;130:1180–1182. [PubMed] [Google Scholar]

5. Tyler A. Urothelial cancers: Ureter, renal pelvis, and bladder. Semin Oncol Nurs. 2012;28:154–162. doi:10.1016/j.soncn.2012.05.004. [PubMed] [CrossRef] [Google Scholar]

6. Ueda T, Okumi M, Ichimaru N, Itoh K, Matsuoka Y, Fujimoto N. Mucinous adenocarcinoma of the renal pelvis in the horseshoe kidney: A case report. Hinyokika Kiyo. 2002;48:187–189. (In Japanese) [PubMed] [Google Scholar]

7. Hudson J, Arnason T, Merrimen JL, Lawen J. Intestinal type villous adenoma of the renal pelvis. Can Urol Assoc J. 2013;7:E138–E142. doi:10.5489/cuaj.257. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Ackerman LV. Mucinous adenocarcinoma of the pelvis of the kidney. J Urol. 1946;55:36. [PubMed] [Google Scholar]

9. Punia RP, Mundi I, Arora K, Dalal A, Mohan H. Primary adenocarcinoma of ureter mimicking pyelonephritis. Urol Ann. 2010;2:42–43. doi:10.4103/0974-7796.62914. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10. Yonekawa M, Hoshida Y, Hanai J, Tuboniwa N, Katayama K, Kishimoto T, Aozasa K. Catheterized urine cytology of mucinous carcinoma arising in the renal pelvis. A case report. Acta Cytol. 2000;44:442–444. doi:10.1159/000328495. [PubMed] [CrossRef] [Google Scholar]

11. Xambre L, Cerqueira M, Cardoso A, Correia T, Dias Macedo A, Carreira F, Galán T. Primary mucinous adenocarcinoma of the renal pelvis - adicional case report] Actas Urol Esp. 2009;33:200–204. doi:10.1016/S0210-4806(09)74124-5. [PubMed] [CrossRef] [Google Scholar]

12. Abbas M, Kramer MW, Spieker T, Herrman TR, Merseburger AS, Müller KM, Kuczyk MA, Becker JU, Kreipe HH. Primary mucinous adenocarcinoma of the renal pelvis with carcinoma in situ in the ureter. J Egypt Natl Canc Inst. 2014;26:51–54. doi:10.1016/j.jnci.2013.11.002. [PubMed] [CrossRef] [Google Scholar]

13. Zhong M, Gersbach E, Rohan SM, Yang XJ. Primary adenocarcinoma of the urinary bladder: Differential diagnosis and clinical relevance. Arch Pathol Lab Med. 2013;137:371–381. doi:10.5858/arpa.2012-0076-RA. [PubMed] [CrossRef] [Google Scholar]

14. Zhang H, Jiang H, Wu Z, Fang Z, Fan J, Ding Q. Primary adenocarcinoma of the urinary bladder: A single site analysis of 21 cases. Int Urol Nephrol. 2013;45:107–111. doi:10.1007/s11255-012-0305-y. [PubMed] [CrossRef] [Google Scholar]

15. Roy S, Parwani AV. Adenocarcinoma of the urinary bladder. Arch Pathol Lab Med. 2011;135:1601–1605. doi:10.5858/arpa.2009-0713-RS. [PubMed] [CrossRef] [Google Scholar]

16. Ploeg M, Aben KK, van de Hulsbergen Kaa CA, Schoenberg MP, Witjes JA, Kiemeney LA. Clinical epidemiology of nonurothelial bladder cancer: Analysis of the Netherlands Cancer Registry. J Urol. 2010;183:915–920. doi:10.1016/j.juro.2009.11.018. [PubMed] [CrossRef] [Google Scholar]

17. Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, el-Baz MA. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol. 2008;180:121–127. doi:10.1016/j.juro.2008.03.024. [PubMed] [CrossRef] [Google Scholar]

18. Cho SY, Moon KC, Park JH, Kwak C, Kim HH, Ku JH. Outcomes of Korean patients with clinically localized urachal or non-urachal adenocarcinoma of the bladder. Urol Oncol. 2013;31:24–31. doi:10.1016/j.urolonc.2010.10.002. [PubMed] [CrossRef] [Google Scholar]

19. Wright JL, Porter MP, Li CI, Lange PH, Lin DW. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer. 2006;107:721–728. doi:10.1002/cncr.22059. [PubMed] [CrossRef] [Google Scholar]

20. Mostofi FK, Thomson RV, Dean AL., Jr Mucous adenocarcinoma of the urinary bladder. Cancer. 1955;8:741–758. doi:10.1002/1097-0142(1955)8:4<741::AID-CNCR2820080417>3.0.CO;2-C. [PubMed] [CrossRef] [Google Scholar]

21. Dandekar NP, Dalal AV, Tongaonkar HB, Kamat MR. Adenocarcinoma of bladder. Eur J Surg Oncol. 1997;23:157–160. doi:10.1016/S0748-7983(97)80012-1. [PubMed] [CrossRef] [Google Scholar]

22. Wang HL, Lu DW, Yerian LM, Alsikafi N, Steinberg G, Hart J, Yang XJ. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol. 2001;25:1380–1387. doi:10.1097/00000478-200111000-00005. [PubMed] [CrossRef] [Google Scholar]

23. Torenbeek R, Lagendijk JH, Van Diest PJ, Bril H, van de Molengraft FJ, Meijer CJ. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology. 1998;32:20–27. doi:10.1046/j.1365-2559.1998.00328.x. [PubMed] [CrossRef] [Google Scholar]

24. Suh N, Yang XJ, Tretiakova MS, Humphrey PA, Wang HL. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol. 2005;18:1217–1222. doi:10.1038/modpathol.3800407. [PubMed] [CrossRef] [Google Scholar]

25. Raspollini MR, Nesi G, Baroni G, Girardi LR, Taddei GL. Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder. Appl Immunohistochem Mol Morphol. 2005;13:358–362. doi:10.1097/01.pai.0000136552.44045.0f. [PubMed] [CrossRef] [Google Scholar]

26. Lauritzen AF, Kvist E, Bredesen J, Luke M. Primary carcinoma of the upper urinary tract. Acta Pathol Microbiol Immunol Scand A. 1987;95:7–10. [PubMed] [Google Scholar]

27. Maskey Sidharth P, Chalise PR, Shrestha A, Sharma UK, Gyawali PR, Shrestha GK, Joshi BR. Primary mucinous adenocarcinoma of the renal pelvis and ureter. Nepal Med Coll J. 2011;13:229–230. [PubMed] [Google Scholar]

Articles from Oncology Letters are provided here courtesy of Spandidos Publications

Primary adenocarcinoma of the renal pelvis, ureter and the urinary bladder: A case report and review of the literature (2024)

FAQs

What is primary adenocarcinoma of the renal pelvis? ›

Abstract: Primary mucinous adenocarcinoma of the renal pelvis is a rare malignant disease that is difficult to diagnose preoperatively. There are still no characteristic symptoms, radiological features, or standard treatment for this tumor with only ~100 cases reported. The prognosis is poor.

What is a primary adenocarcinoma of the urinary bladder? ›

Primary adenocarcinoma of the bladder is malignant tumor with histologically pure glandular differentiation. It accounts for 0.5-2% of all primary bladder malignancies. This tumor is more common in men than in women. Patients are usually in the sixth-seventh decade of life.

Which is the most common malignancy of the urinary bladder and ureter? ›

Greater than 90% of urinary tract cancers are transitional cell carcinomas (TCC) known today as urothelial carcinomas (UC).

What is a cancer of the renal pelvis or ureter? ›

Cancer of the renal pelvis or ureter is cancer that forms in the kidney's pelvis or the tube (ureter) that carries urine from the kidney to the bladder.

What is the prognosis for adenocarcinoma of the bladder? ›

The 5-year relative survival rate of people with bladder cancer that has not spread beyond the inner layer of the bladder wall is 96%. Almost half of people are diagnosed with this stage. If the tumor is invasive but has not yet spread outside the bladder, the 5-year relative survival rate is 70%.

Is adenocarcinoma of the bladder aggressive? ›

In general, bladder cancers that are muscle invasive and/or have high-grade cells are the most serious and aggressive. The less common types of bladder cancer such as squamous cell carcinoma, adenocarcinoma, and small cell carcinoma have a greater tendency to be muscle invasive compared to urothelial carcinoma.

How is primary bladder adenocarcinoma treated? ›

When the cancer has invaded the muscle, radical cystectomy (removal of the bladder) is the standard treatment. Lymph nodes near the bladder are often removed as well. If cancer is in only one part of the bladder, a partial cystectomy may be done instead. But this is possible in only a small number of patients.

Is adenocarcinoma of the bladder rare? ›

Adenocarcinoma. This is a very rare type of bladder cancer. Between 1 and 2 out of every 100 people (1 to 2%) diagnosed with bladder cancer have it. It is usually invasive.

What is the most common first symptom of a malignant tumor of the bladder? ›

For most people, the first symptom of bladder cancer is blood in the urine, also called hematuria.

What are the two most common cancers that urologists see? ›

Bladder cancer. Kidney (renal) cancer.

What is the life expectancy for urothelial carcinoma? ›

If the cancer extends through the bladder to the surrounding tissue or has spread to nearby lymph nodes or organs, the five-year survival rate is 39%. If the cancer has spread to distant parts of the body, the five-year survival rate is 8%. About 4% of people are diagnosed at this stage.

Is ureter cancer aggressive? ›

Invasive urothelial carcinoma

When this happens, cancer of the renal pelvis or ureter usually grows and spreads faster (it is aggressive). It is then more likely to be diagnosed when it's advanced. Squamous cells, gland cells and small cells are most commonly found mixed with urothelial cancer cells.

Can renal pelvis cancer be cured? ›

In general, lower-stage and lower-grade cancers have a better prognosis than high-stage and high-grade cancers. It's helpful to get an early diagnosis of transitional cell cancer of the renal pelvis and ureter because the disease is highly curable when it's treated before it spreads.

Can you survive ureter cancer? ›

The 5-year net survival for both kidney cancer and renal pelvis cancer together is 71%. This means that about 71% of people diagnosed with kidney cancer or renal pelvis cancer will survive at least 5 years. In Canada, the 5-year net survival for cancer of the ureter is 46%.

What is the most common presentation of renal adenocarcinoma? ›

In one review of 309 consecutive patients with RCC, the most common presenting symptoms were hematuria, abdominal mass, pain, and weight loss [2].

What is a renal adenocarcinoma? ›

(REE-nul sel A-deh-noh-KAR-sih-NOH-muh) Cancer that begins in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Renal cell adenocarcinoma is the most common type of kidney cancer in adults.

What is the survival rate for urothelial carcinoma of the renal pelvis? ›

Survival by grade and stage
Grade and stage5-year survival rate
The cancer is low grade and has not grown beyond the connective tissue layer (lamina propria).100%
The cancer is grade 1, 2 or 3 and only in the inner lining (urothelium).80%
The cancer is high grade and has grown into the wall of the pelvis.20% to 30%
1 more row

What is the prognosis for primary peritoneal adenocarcinoma? ›

The overall survival rate for primary peritoneal cancer may be between 11 and 17 months, according to the same 2022 review .

Top Articles
Latest Posts
Article information

Author: The Hon. Margery Christiansen

Last Updated:

Views: 6546

Rating: 5 / 5 (50 voted)

Reviews: 81% of readers found this page helpful

Author information

Name: The Hon. Margery Christiansen

Birthday: 2000-07-07

Address: 5050 Breitenberg Knoll, New Robert, MI 45409

Phone: +2556892639372

Job: Investor Mining Engineer

Hobby: Sketching, Cosplaying, Glassblowing, Genealogy, Crocheting, Archery, Skateboarding

Introduction: My name is The Hon. Margery Christiansen, I am a bright, adorable, precious, inexpensive, gorgeous, comfortable, happy person who loves writing and wants to share my knowledge and understanding with you.